Targeted drug for advanced biliary tract cancer after standard treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new targeted drug (SHR-A1904) in people with advanced biliary tract cancer whose tumors have a specific protein (Claudin18.2) and who have already tried at least one standard treatment. The goal is to see if this drug can shrink the cancer or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have biliary tract cancer (cancer in the bile ducts or gallbladder) that has spread or cannot be removed with surgery.
- Your tumor is positive for a protein called Claudin18.2 (doctors will test for this).
- You've already had at least one type of chemotherapy or drug treatment for your cancer, and it either stopped working or you couldn't handle the side effects.
- You are generally well enough to do daily activities (like walking around or light housework).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
This trial tests a combination treatment for biliary tract cancer that is borderline resectable or locally advanced. It combines a chemotherapy infusions directly into the liver (HAIC) with an immunotherapy drug (adebrelimab) and a targeted therapy pill (lenvatinib), aiming to shrink the tumor enough to allow surgery.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new drug called SHR-A1904 for people with advanced neuroendocrine carcinoma that has grown after standard chemotherapy. The drug is given alone and may help shrink tumors or slow the disease.
This trial tests a new drug, SHR-A1811, for people with HER2-positive bile duct cancer that has spread or cannot be removed by surgery. It may help control the cancer if you haven't had other treatments for this stage.
This trial is testing whether a new drug (SHR-8068) combined with adebrelimab and chemotherapy works better than the current standard treatment for people with advanced bile duct cancer who have not been treated yet.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.